BioRestorative Therapies, a life sciences company focused on stem cell-based therapies, announced the Australia Patent Office (APO), a division of IP Australia - an agency of the Department of Industry, has issued a Notice of Acceptance for the company’s patent application covering methods related to BioRestorative’s metabolic programme (ThermoStem Programme). Following the Notice of Acceptance, the company is required to pay the associated fees and the patent should be issued.

This will be the second patent issued for the company’s brown fat technology, and follows a patent the company was issued in the United States in November 2015.

Once issued in Australia, the final patent will allow for the protection of methods of generating stem cells and stem cell lines from brown adipose tissue (brown fat) under xeno-free (animal-free) conditions utilizing a proprietary differentiating medium. The technology is applicable for potential therapeutic uses for treating a wide range of degenerative and metabolic disorders, including but not limited to diabetes, hypertension, cardiac deficiency and obesity.

“This Notice of Acceptance on our patent application for the metabolic program is an important next step as we look to rapidly expand the intellectual property protection surrounding our brown fat program around the world,” said Mark Weinreb, president and chief executive officer. “In particular, we are actively exploring a number of international opportunities, including grants and potential strategic partners, as we seek to advance the program toward clinical trials. We are excited about the potential of our proprietary stem cell technology in the treatment of metabolic disorders such as diabetes and hypertension.”

BioRestorative Therapies, develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.